Overview
InspireMD Q2 revenue rises 2.3%, beating analyst expectations, per LSEG data
Net income for Q2 missed analyst expectations, per LSEG data
Co received FDA approval and launched CGuard Prime in U.S. market
Outlook
Company plans to launch CGuard Prime in Europe in Q3
InspireMD focuses on scaling operations post-U.S. launch
Company aims to establish CGuard as standard for carotid disease
Result Drivers
FDA APPROVAL - Received FDA approval for CGuard Prime carotid stent system, driving U.S. market launch
EXCHANGE RATES - Revenue positively impacted by exchange rates, offsetting decreased revenue from Russia
OPERATING EXPENSES - Increased due to U.S. sales force expansion and CGuard Prime launch preparation
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $1.78 mln | $1.52 mln (2 Analysts) |
Q2 Net Income | Miss | -$13.15 mln | -$12.90 mln (2 Analysts) |
Q2 Income From Operations | Beat | -$13.02 mln | -$13.10 mln (2 Analysts) |
Q2 Basic EPS | -$0.26 | ||
Q2 Gross Profit | $313,000 | ||
Q2 Operating Expenses | $13.33 mln |
Press Release: ID:nGNX4ZbSXW
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.